Verastem reports 2-year RAMP 201 data for avutometinib-defactinib combo
Company says follow-up data reinforced durable responses and disease control in recurrent LGSOC, with no new safety signals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Verastem Oncology says Gynecologic Oncology published RAMP 201 follow-up data
The company said the journal published two-year follow-up data from its Phase 2 RAMP 201 study of AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer. Verastem cited median duration of response of 31.1 months and no new safety signals.